Monopar Therapeutics Inc. Cash and Cash Equivalents, Fair Value Disclosure
Monopar Therapeutics Inc. (MNPR) had Cash and Cash Equivalents, Fair Value Disclosure of $4.47 million as of 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Notes › Fair Value Disclosures
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2023-05-11
- 2023-03-31: Cash and Cash Equivalents, Fair Value Disclosure $4.47M.
- 2022-12-31: Cash and Cash Equivalents, Fair Value Disclosure $7.25M.
- 2022-09-30: Cash and Cash Equivalents, Fair Value Disclosure $13.92M.
- 2022-06-30: Cash and Cash Equivalents, Fair Value Disclosure $16.06M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure |
|---|---|
| 2023-03-31 | $4.47M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $7.25M 10-Q · filed 2023-05-11 |
| 2022-09-30 | $13.92M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $16.06M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $17.60M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $20.01M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |